Rob has been at AstraZeneca since 2016 where he leads the Discovery Biology department part of the Biopharmaceuticals organisation. The group, based in Gothenburg, Sweden, supports early stage drug discovery projects providing reagents and assays with a focus on cardiovascular, metabolic and respiratory disease areas.
Previously he worked at MedImmune, the biologics arm of AstraZeneca, from 2013 to 2016 where he led the Biologics Profiling team. He started his industrial career in 2001 at Vernalis, a UK biotech company focused on developing cancer therapeutics using structure-based drug design. He held various positions culminating in leading the HTS group as well as impacting on several small molecule research programmes. In 2008 he joined Horizon Discovery a UK biotech company developing the rAAV genome editing technology as Research Director. He built several teams and labs in the UK and Italy before transitioning to Principal Scientist to lead collaborations with over 50 academic groups across the globe.
Rob obtained his PhD in Molecular Biology from the University of Cambridge studying EGF signalling under the mentorship of Matthew Freeman at the Medical Research Councils Laboratory of Molecular Biology. Prior to starting an industrial career he completed Postdoctoral Fellowships at Stanford University in the lab of Roel Nusse and later at the University of Cambridge in the lab of Sarah Bray studying the role of Frizzled receptors in Wnt signalling.
Rob has more than 20 publications and has been an invited speaker/presenter at over 30 scientific venues. He serves on the editorial board of SLAS Discovery and has advised/chaired at several conferences including SLAS 2017/2018/2020.